FDA Discloses Safety Reviews Of Arcoxia, Prexige and Parecoxib
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's Arcoxia (etoricoxib) shows an increase in cardiovascular adverse events in "a number of analyses," FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review
You may also be interested in...
Pfizer’s COX-2 Parecoxib Is “Not Approvable”
Company plans to meet with FDA regarding status of injectable COX-2 agent “as soon as possible.”
Pfizer’s COX-2 Parecoxib Is “Not Approvable”
Company plans to meet with FDA regarding status of injectable COX-2 agent “as soon as possible.”
COX-2 Pipeline Drugs Will Need Additional Cardiovascular Data, FDA Says
COX-2 inhibitors in the R&D pipeline will need additional cardiovascular safety data prior to approval under FDA's risk management program for the drug class